Regeneron Announces FDA Has Extended The Approval Of Praluent To Include Patients Aged 8 And Older With HeFH
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals has announced that the FDA has extended the approval of its drug Praluent to include treatment for patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH).
March 11, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's extension of Praluent's approval to younger patients with HeFH could lead to increased sales and market expansion for Regeneron.
The FDA approval for a broader patient demographic directly impacts Regeneron's market potential for Praluent. This expansion into a younger age group could significantly increase the drug's user base, leading to higher sales and potentially positive investor sentiment towards REGN's stock in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90